{
    "clinical_study": {
        "@rank": "109262", 
        "arm_group": [
            {
                "arm_group_label": "ALS-008176", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety, tolerability, and pharmacokinetics (PK) of orally\n      administered ALS-008176 in healthy volunteers."
        }, 
        "brief_title": "Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Respiratory Syncytial Virus Infections", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Syncytial Virus Infections", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects, 18-55 years of age, in good health with screening laboratory\n             values within limits specified by the protocol\n\n          -  Body mass index 18-30 kg/m2\n\n          -  Female subjects must be of non-childbearing potential; male subjects must be\n             surgically sterile or practicing birth control\n\n        Exclusion Criteria:\n\n          -  Clinically significant or uncontrolled medical illness\n\n          -  Use, or anticipated use during conduct of the study, of concomitant medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01906164", 
            "org_study_id": "ALS-8176-501", 
            "secondary_id": "2012-004894-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALS-008176", 
                "intervention_name": "ALS-008176", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "RSV", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France"
                }, 
                "name": "Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing, Multiple Ascending Dosing and Food-effect in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Alios BioPharma", 
            "last_name": "Matthew McClure, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety data including, but not limited to, tabulation of adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urine)", 
            "safety_issue": "Yes", 
            "time_frame": "11 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01906164"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PK parameters of ALS-008176 and metabolites in plasma following single dose administration: Cmax, tmax, t1/2, CL/F and Vdss/F (not for metabolites), AUC0-24h, AUC0-inf or AUC0-last", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "PK parameters of ALS-008176 and metabolites in plasma following repeat dose administration: Cmax, Cmin, tmax, t1/2, CL/F and Vdss/F (not for metabolites), AUC0-24h , AUC0-last and AUC0 tau", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Urinary excretion and concentrations of ALS-008176 and metabolites after a single oral dose and multiple doses in healthy volunteers in fasted conditions", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "PK parameters of ALS-008176 and metabolites in plasma after a single oral dose in healthy volunteers in fasted conditions as compared with fed conditions: Cmax, tmax, t1/2, CL/F and Vdss/F (not for metabolites), AUC0-24h, AUC0-inf or AUC0-last", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }
        ], 
        "source": "Alios Biopharma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alios Biopharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}